Thyroid hormone and the stunned myocardium.

Area of Science:

• Endocrinology
• Cardiology
• Critical Care Medicine

Background:

• Critically ill patients often develop euthyroid sick syndrome (ESS), characterized by altered thyroid hormone levels (decreased FT3/FT4, increased reverse T3).
• ESS is frequently associated with myocardial depression, termed 'stunned myocardium', ranging from mild impairment to cardiogenic shock.

Purpose of the Study:

• To investigate the efficacy of thyroid hormone (T3/T4) therapy in patients with ESS and associated myocardial dysfunction.
• To evaluate the impact of T3/T4 therapy on myocardial energy metabolism and function in specific ischemic conditions.

Main Methods:

• Studied three conditions with ESS and myocardial depression: transient regional ischemia/reperfusion, transient global ischemia during cardiac surgery, and inadequate perfusion in brain-dead organ donors.
• Assessed changes in high-energy phosphates, myocardial lactate, and cytosolic calcium homeostasis following T3/T4 administration.

Main Results:

• Myocardial ischemia in these conditions led to depletion of high-energy phosphates and lactate accumulation.
• Administration of T3/T4 therapy resulted in rapid reversal of myocardial dysfunction across all three studied conditions.

Conclusions:

• Thyroid hormone therapy (T3/T4) demonstrates potential in rapidly reversing myocardial dysfunction associated with ESS and stunned myocardium.
• Cautious advocacy for T3/T4 therapy is suggested for patients presenting with ESS and/or stunned myocardium.